Treating nausea and vomiting in palliative care: a review by Glare, Paul et al.
© 2011 Glare et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2011:6 243–259
Clinical Interventions in Aging Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
243
RevIew
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CIA.S13109
Treating nausea and vomiting in palliative  
care: a review
Paul Glare
Jeanna Miller
Tanya Nikolova
Roma Tickoo
Pain and Palliative Care Service, 
Department of Medicine, Memorial 
Sloan-Kettering Cancer Center,  
New York, NY, USA
Correspondence: Paul Glare 
Memorial Sloan-Kettering Cancer Center, 
1275 York Avenue, New York,  
NY 10065, USA 
Tel +1 646 888 3124 
Fax +1 646 422 0937 
email glarep@mskcc.org
Abstract: Nausea and vomiting are portrayed in the specialist palliative care literature as 
common and distressing symptoms affecting the majority of patients with advanced cancer and 
other life-limiting illnesses. However, recent surveys indicate that these symptoms may be less 
common and bothersome than has previously been reported. The standard palliative care approach 
to the assessment and treatment of nausea and vomiting is based on determining the cause and 
then relating this back to the “emetic pathway” before prescribing drugs such as dopamine 
antagonists, antihistamines, and anticholinergic agents which block neurotransmitters at differ-
ent sites along the pathway. However, the evidence base for the effectiveness of this approach 
is meager, and may be in part because relevance of the neuropharmacology of the emetic pathway 
to palliative care patients is limited. Many palliative care patients are over the age of 65 years, 
making these agents difficult to use. Greater awareness of drug interactions and QTc prolonga-
tion are emerging concerns for all age groups. The selective serotonin receptor antagonists are 
the safest antiemetics, but are not used first-line in many countries because there is very little 
scientific rationale or clinical evidence to support their use outside the licensed indications. 
Cannabinoids may have an increasing role. Advances in interventional gastroenterology are 
increasing the options for nonpharmacological management. Despite these emerging issues, 
the approach to nausea and vomiting developed within palliative medicine over the past 40 years 
remains relevant. It advocates careful clinical evaluation of the symptom and the person suf-
fering it, and an understanding of the clinical pharmacology of medicines that are available for 
palliating them.
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Introduction
In the specialist palliative care literature, nausea and vomiting have long been presented 
as common and distressing symptoms affecting the majority of patients.1 The corner-
stone of the assessment and treatment of nausea and vomiting in palliative care has 
been based on the understanding of the “emetic pathway” and the main neurotransmit-
ters involved in this process.2,3 This is because antiemetic drugs are predominately 
neurotransmitter-blocking agents at the different receptor sites involved in this process. 
The supposition has been that knowing where the various neurotransmitters occur in 
this pathway will lead to rational selection of antiemetic agents that will be effective 
in managing different causes of vomiting.
The value of this approach was emphasized in the case report “A woman with 
malignant bowel obstruction who did not want to die with tubes”.4 An elderly patient 
with worsening nausea and vomiting due to a mechanical obstruction of the small Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
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bowel was well palliated with antiemetics (plus octreotide) 
until death occurred a short time later, averting the need for 
a laparotomy or placement of a drainage gastrostomy tube. 
Despite successful palliation outcomes obtained in such 
cases, the traditional approach to managing nausea and 
vomiting in palliative care has been challenged in recent 
years for a number of reasons:
•	 Surveys indicate these symptoms may be less common 
and bothersome than has previously been estimated.
•	 The emetic pathway was primarily determined to facilitate 
new drug development for chemotherapy-induced emesis 
and may not be particularly relevant to treating nausea 
and vomiting occurring in palliative care patients.
•	 When attempts are made to determine a cause in palliative 
care patients, either none can be found or else multiple 
causes are identifiable.
•	 Even if a single cause is identifiable, the neuropharmacol-
ogy of the pathway is largely redundant, because many 
antiemetics have a broad spectrum of neurotransmitter-
blocking activity and work at multiple sites.
•	 The evidence base for this approach is modest, and the 
high response rates reported in case series and uncontrolled 
studies are often not borne out in the small number of well 
designed clinical trials that have been undertaken.
•	 Other pathways, such as the cytokine immunologic model 
of cancer symptoms,5 may also be relevant.
•	 Advances in interventional gastroenterology and radiol-
ogy are increasing the options for nonpharmacological 
management.
Notwithstanding these challenges, the traditional 
approach still has merits even if its basic science is limited, 
because it provides a scholarly basis for approaching the 
pharmacological palliation of nausea and vomiting in patients 
with life-limiting illnesses. The traditional approach advo-
cates careful clinical evaluation of the symptom and the 
person suffering it, and understanding the clinical pharmacol-
ogy of the medicines that are available. The aim of this paper 
is to review the traditional approach to the assessment and 
treatment of chronic nausea and vomiting in patients with 
life-limiting illnesses in the light of the challenges listed 
above. Because many palliative care patients are over the 
age of 65 years, especially those with noncancer diagnoses, 
treatment of nausea and vomiting with antiemetic drugs can 
be more difficult in these geriatric patients than in younger 
ones. Physiologic changes such as diminished renal function, 
changes in body fat distribution, and alterations in hepatic 
metabolism, can lead to higher levels of medications and a 
greater susceptibility to adverse effects.6 Special reference 
will be made to pharmacological considerations that are 
necessary when prescribing antiemetics in older patients. 
Advances in health care and changing demographics world-
wide have led to an aging population in whom care at the 
end of life has become increasingly complicated.7
While there is reasonably good evidence for the palliation 
of bowel obstruction,8 symptom management of the actively 
treated elderly cancer patient represents an undertreated and 
disproportionately understudied cohort in oncology.9 This is 
certainly the case for nausea and vomiting. A MEDLINE 
search retrieved no citations for “nausea and vomiting” or 
“palliative care”, when limited to human subjects, English 
language, and age over 65 years. Entering the same terms in 
the clinical trials database maintained by the US National 
Library of Medicine (www.clinicaltrials.gov) identified 19 
trials, but none evaluating pharmacological therapies in this 
population, and none being specifically for the elderly.
Epidemiology of nausea  
and vomiting in palliative care
Symptom research is complicated because many factors con-
found the patient’s experience of symptoms. This is even more 
so in patients receiving palliative care because the observa-
tional studies needed are methodologically challenging for 
several   reasons.10 Firstly, there is great heterogeneity in the 
clinical status of palliative care populations. They have many 
different primary diseases, at various stages. They often have 
symptomatic comorbidities. Secondly, differences in study set-
ting, ie, hospital ward, outpatient clinic, inpatient unit, or home 
care, will impact on incidence and prevalence. Thirdly, nausea 
and vomiting tend to be treated as a single entity when they are 
not, eg, in one study, 62% had both nausea and vomiting, 34% 
had isolated nausea, and 4% had isolated vomiting.11 Fourthly, 
the impact of treatment confounds the data – does one include 
a patient whose nausea and vomiting are currently completely 
relieved by antiemetic therapy, or not? Lastly, there is no stan-
dardized tool for measuring nausea and vomiting.12–14
Despite these methodological challenges, it now appears 
that nausea and vomiting may be less common and bothersome 
than has previously been estimated. A systematic review of the 
prevalence of common symptoms in patients with various 
life-limiting illnesses found that pain, breathlessness, and 
fatigue were all more common than nausea and vomiting.10 
While the first three symptoms were each reported by more 
than 50% of patients with cancer, heart failure, renal failure, 
or the acquired immunodeficiency syndrome (AIDS), nausea 
and vomiting were only reported by 16%–68% of patients. 
Nausea and vomiting occurred most commonly in patients Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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with AIDS, being reported by at least 43% of patients, followed 
by at least 30% of end-stage renal failure patients, at least 17% 
of heart failure patients, and at least 6% of cancer patients.
The findings of the above review have been confirmed in 
several recent studies of nausea and vomiting in palliative care 
populations.15–17 Nausea and vomiting do appear to become 
more common as death approaches, so it is not surprising that 
nausea has been found to be a predictor of a shortened survival 
in one study.18 In patients admitted to specialist palliative care 
programs, nausea has been reported by 36% patients at the 
first contact with the service,19–21 62% at 1–2 months before 
death,22,23 and 71% in the final week of life.24,25 However, in 
one study, the prevalence of nausea peaked in patients with a 
Karnofsky performance status score of 40, then decreased as 
performance status declined further, indicating it may often 
be aggravated by movement and alleviated by resting.26
While nausea is an unpleasant experience and nobody 
likes to vomit, these symptoms may be intermittent in pallia-
tive care patients, and are typically only mild to moderate in 
severity when present. Nausea was rated only 3–4 out of 
10 in intensity in one study,17 and was moderate-to-severe 
(greater than 5 out of 10) in only a quarter of cases in 
  another.27 In this sample, the impact of nausea and vomiting 
on general activity and emotional well being was rated as 
greater than 5 out of 10 by approximately 40% of patients. 
A recent, very large, population-based, prospective survey 
of 10 symptoms in ambulatory advanced cancer patients in 
Canada followed prospectively until death, found nausea was 
the least bothersome symptom, being moderate-severe in 
only 10% cases.16 Similar to pain, nausea and vomiting have 
been reported to be frequently undertreated,28 and perhaps 
surprisingly, it is the patients with more severe symptoms 
who often miss out on antiemetic therapy.29
In patients receiving palliative care, nausea and vomiting 
rarely occur in isolation. They tend to cluster with other 
symptoms like fatigue, drowsiness, decreased appetite, and 
dyspnea.30 Symptom clusters are important because they may 
independently predict changes in patient function, treatment 
failures, and post-therapeutic outcomes. Treatments directed 
at symptom clusters rather than individual symptoms may 
provide greater therapeutic benefit. In a review of symptom 
clustering in advanced cancer, many of the studies included 
found nausea and vomiting did cluster independently and 
not with other symptoms.
Definitions of nausea and vomiting
Clarification of the definitions of nausea, vomiting, and 
related phenomena is important for the correct assessment 
and treatment of these symptoms in patient receiving pallia-
tive care. This is because these terms are both poorly under-
stood and incorrectly used.31 Nausea is an entirely subjective 
experience, defined as “the sensation (or sensations) that 
immediately precede vomiting”. Patients state that they feel 
as if they are about to vomit, or describe the sensation as 
feeling “queasy” or “sick to the stomach”. Vomiting, in 
contrast, is a highly specific physical event, defined as “the 
rapid, forceful evacuation of gastric contents in retrograde 
fashion from the stomach up to and out of the mouth”. 
  Vomiting is usually, but not always, proceeded by nausea. 
Retching is the repetitive, active contraction of the abdominal 
musculature, generating the pressure gradient which leads 
to evacuation of stomach contents. Retching may occur in 
isolation without discharge of gastric contents from the 
mouth, referred to as “dry heaves”. Nausea and vomiting 
need to be distinguished from:
•	 Regurgitation – passive, retrograde flow of esophageal 
contents into the mouth. Regurgitation occurs with gas-
troesophageal reflux or esophageal obstruction.
•	 Rumination – an eating disorder which may be confused 
with vomiting. Rumination occurs repetitively after 
meals, is not preceded by nausea, and is not associated 
with the physical phenomena normally accompanying 
vomiting.
•	 Dyspepsia – chronic or recurrent pain or discomfort 
centered in the upper abdomen. Dyspepsia can be 
  classified as structural (acid-related) or functional 
(  dysmotility-related).32,33 Functional dyspepsia in cancer 
patients is called the cancer-associated dyspepsia 
syndrome,34 characterized by nausea, early satiety, post-
prandial fullness, and pain.
Causes of nausea and vomiting
Nausea and vomiting is referred to as “chronic” if it is present 
for more than a few days, and the median duration in palliative 
care has been reported as seven days (range 1–468).17 Chronic 
nausea and vomiting present a greater diagnostic and thera-
peutic challenge than acute nausea and vomiting, and can 
usually be diagnosed readily on clinical grounds alone. There 
are many possible causes for nausea and vomiting in patients 
with advanced disease.35 The broad differential includes all 
the usual causes of nausea and vomiting shown in Table 3. In 
addition, etiologies specific to life-limiting illnesses need to 
be added to the list (see Table 1). It can be helpful to arrange 
the differential into the four categories which are used for 
classifying the etiology of cancer pain, ie, due to the primary 
disease, due to a side effect of therapy, secondary to Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Categorization of nausea etiology in elderly palliative care patients with various life-threatening illnesses
Cancer Cardiac failure Chronic obstructive  
pulmonary disease
End-stage  
renal failure
Dementia
Disease Liver metastases,  
bowel obstruction
edema of  
gastrointestinal tract
Post-tussive vomit Uremia -
Treatment Chemotherapy,  
opioids, NSAIDs
Hyponatremia,  
digoxin toxicity
Antibiotics,  
theophylline,
Dialysis, peritonitis Cholinesterase  
inhibitors
Debility Constipation,  
esophageal candida,  
anxiety, cachexia
Constipation,  
esophageal candida,  
anxiety, cachexia
Constipation,  
esophageal candida,  
anxiety, cachexia
Constipation,  
esophageal candida,  
anxiety, cachexia
Constipation,  
esophageal candida,  
tube feedings cachexia
Unrelated Mesenteric ischemia,  
subacute cholangitis,  
Meniere’s disease  
gastroenteritis
Mesenteric ischemia,  
subacute cholangitis,  
Meniere’s disease  
gastroenteritis
Mesenteric ischemia,  
subacute cholangitis,  
Meniere’s disease  
gastroenteritis
Mesenteric ischemia,  
subacute cholangitis,  
Meniere’s disease  
gastroenteritis
Mesenteric ischemia,  
subacute cholangitis,  
Meniere’s disease  
gastroenteritis
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
  debilitation, and caused by an unrelated comorbid condition. 
Because palliative care may be provided concurrent with 
disease-controlling treatment, entities such as chemotherapy-
induced emesis and postoperative nausea and vomiting may 
also occur in this population. Discussion of these topics is 
beyond the scope of this review, but readers are referred to the 
various consensus guidelines for the management of these 
problems.36,37 In elderly palliative care patients, conditions such 
as mesenteric ischemia, subacute cholangitis, Meniere’s disease, 
myocardial infarction, drug toxicity, constipation, and urinary 
tract infection need to be high on the differential diagnosis of 
nausea and vomiting. An etiology can be identified in approxi-
mately two thirds to three quarters of nauseated patients in 
palliative care.11,38,39 Multiple etiologies often coexist.
Certain demographic and clinical factors predict the 
development of nausea in palliative care patients. Nausea 
has been reported to be less common in patients over the age 
of 65 years.40 Other risk factors include female gender,40 
specific tumor types (most notably gynecological, stomach, 
esophageal, and breast cancers),1,21 presence of metastases 
in the lung, pleura, or peritoneum,41 gastrointestinal pathol-
ogy or intestinal obstruction,42 and opioid medication.43
Assessment of nausea
There are four concurrent goals to be accomplished when 
evaluating the patient with advanced disease who reports 
nausea and vomiting:
•	 To clarify whether the patient is reporting nausea, dys-
pepsia, vomiting, retching, or regurgitation.
•	 To determine the etiology, in case it is easily reversed 
or treated.
•	 To document the intensity, frequency and associated   distress. 
If possible, a patient-rated assessment of nausea should be 
obtained, preferably using a symptom   assessment tool.12–14 
The psychosocial and spiritual   dimensions of suffering 
associated with the life-limiting illness should also be 
addressed, because these may contribute to the distress 
caused by the nausea and vomiting.44
•	 To commence appropriate antiemetic therapy. Unless the 
patient is actively dying, this should include identification 
and correction of any dehydration, electrolyte deficien-
cies, and acid-base disturbances caused by prolonged 
vomiting.
The history of the nausea and vomiting is the cornerstone 
to determining its etiology in palliative care. In addition to 
delineating the duration, frequency, and severity of the nausea 
and vomiting, the history should elicit a description of their 
characteristics and the nature of any associated symptoms. 
It is important to clarify if the nausea and vomiting are occur-
ring together or in isolation. Associated problems such as 
reflux, gastric irritation, and constipation should be ruled out. 
There needs to be a review of the home medication list. The 
history should include sentinel questions which aid determi-
nation of the chronic nausea syndrome. Six have been 
described:11,39
•	 Intermittent nausea associated with early satiety and 
postprandial fullness or bloating. The nausea is relieved 
by vomiting that is usually small volume, occasionally 
forceful, and may contain food. This clinical picture sug-
gests impaired gastric emptying. This is the cause in 
35%–45% cases of nausea and vomiting.
•	 Persistent nausea, aggravated by the sight and smell of 
food, unrelieved by vomiting. This suggests chemical 
causes, activating the chemoreceptor trigger zone. It is 
found in 30%–40% cases.
•	 Intermittent nausea associated with abdominal cramps 
and altered bowel habit. The nausea is relieved by vomit-
ing that may become large in volume and bilious or Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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feculent. This suggests a bowel obstruction and is the 
cause in 10%–30% cases.
•	 Early morning nausea and vomiting associated with 
headache. This suggests raised intracranial pressure.
•	 Nausea aggravated by movement, including motion sick-
ness or even just turning the head. This indicates a ves-
tibular component.
•	 Nausea and vomiting associated with anxiety, suggesting 
a cortical component.
The last three clinical pictures occur in ,15% cases. 
The putative etiology derived from the history is then con-
firmed by the physical examination (eg, fever, uremic 
appearance, abdominal tenderness, hepatomegaly, dimin-
ished bowel sounds, pulmonary edema) and on review of 
any relevant blood tests and radiology. Ordering an abdomi-
nal x-ray is worth considering, except in the most terminally 
ill patient, to help rule out constipation, bowel obstruction, 
or perforation. Unless the history and examination specifi-
cally suggests upper gastrointestinal mucosal disease or an 
abnormality of motor function, tests such as esophagogas-
troduodenoscopy, small bowel series, gastric emptying 
studies, electrogastrography, or antroduodenal manometry 
would not normally be ordered in palliative care patients 
(see Table 2).
Regular reassessment should occur daily to ensure that 
the symptoms remain controlled. This includes reassessment 
of the severity of nausea and vomiting, and the effectiveness 
of the antiemetic regimen, and other treatment strategies. 
A recurrence or exacerbation of previously controlled nausea 
and vomiting requires a full re-evaluation.
Approaches to pharmacological 
treatment of nausea
Pharmacological agents are the principal method for palliat-
ing nausea and vomiting in patients with life-limiting 
  diseases. There are two different approaches to drug   selection, 
Table 3 Chronic nausea and vomiting syndromes in palliative 
care patients with advanced cancer
Syndrome Examples
Gastric stasis Cancer-related 
• Carcinoma of stomach 
• Hepatomegaly or ascites (“squashed stomach”) 
• Paraneoplastic neuropathy 
Treatment-related: 
• Drug-induced, eg, opioids 
Comorbidities: 
• Dyspepsia 
• Gastritis (including drug-related, eg, NSAIDS) 
• Diabetic gastroparesis
Biochemical Cancer-related 
• Hypercalcemia 
• Liver metastases 
• Obstructive uropathy 
• Bowel obstruction 
• “Toxins” (anorexia-cachexia syndrome) 
Treatment-related 
• Drugs: opioids, chemotherapy 
Comorbidities 
• Organ failures 
• Infections 
• Drugs: antibiotics, SSRI antidepressants
Raised intracranial  
pressure
Cancer-related 
• Brain tumors 
• Cerebral secondaries 
• Meningeal disease
vestibular Cancer-related 
• Cerebral secondaries 
Treatment related 
• Drugs, eg, opioids 
Comorbidities 
• Motion sickness, vestibular problems
Bowel obstruction/ 
dysmotility
Cancer-related 
• Bowel primary 
•   Intra-abdominal secondaries  
(eg, peritoneal disease)
• Ascites 
Treatment-related 
• Adhesions 
Debility 
• Constipation
Other • Anxiety
Abbreviations:  NSAIDs,  nonsteroidal  anti-inflammatory  drugs;  SSRIs,  selective 
serotonin reuptake inhibitors.
Table 2 Assessment of the elderly palliative care patient with 
nausea and vomiting
History
Quality: nausea, vomiting, retching, regurgitation
Duration
Persistent or intermittent
Intensity
Associated vomiting, nature of vomitus, relief from vomiting
Associated pain, altered bowel habit
Aggravating factors: sight/smell of food, worse after eating, movement
Temporal factors: worse in morning
Relieving factors eg, vomiting
Drug history: opioids, nonsteroidal anti-inflammatory drugs, antibiotics
Anticancer treatment
Physical examination
Abdomen: organomegaly, other masses, bowel sounds  
(ileus or mechanical obstruction), rectal examination
Other: signs of sepsis, metabolic abnormalities (liver failure, renal failure, 
hypercalcemia), neurological signs
Investigations
Radiology: abdominal x-ray, computed tomography scan, magnetic 
resonance imaging
Laboratory tests: rule out sepsis, renal failure, hypercalcemiaClinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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which may be referred to as empirical and mechanistic. The 
empirical approach leaves antiemetic drug selection to physi-
cian preference. In contrast, the mechanistic approach applies 
our current understanding of the neuropharmacology of the 
“emetic pathway” to the selection of the antiemetic agents 
(see Figure 1).45 These sites contain receptors for one or more 
neurotransmitter, including dopamine type 2 (D2), serotonin 
types 2–4 (5HT2–4), histamine type 1(H1), and acetylcholine 
(muscarinic receptors type 1 to 5, M1–5). Other receptors such 
as substance P, cannabinoid type 1 (CB1) and the endogenous 
opioids may also be implicated, although their precise sites 
are uncertain. Antiemetic selection is based on knowing 
which drugs block the receptors found in the structure where 
the cause of the nausea and vomiting is acting on, inferred 
from the clinical assessment discussed earlier. The neu-
rotransmitter receptors at which the various antiemetic drugs 
are known to work are shown in Table 4. The selected agent 
should be titrated to effect. If the patient does not respond to 
one agent, a second agent should be added, combining agents 
from different classes.
While the mechanistic approach is based on clinical sci-
ence, it has limitations in that the etiology of chronic nausea 
in advanced disease is often unidentifiable or multifactorial, 
many of the drugs act on multiple receptors, and other path-
ways may also be operating.5 Therefore, a more empiric 
approach is justifiable. Because most cases are due to 
  gastroparesis or mediated via the chemoreceptor trigger zone, 
treatment should be initiated with a dopamine antagonist. 
In patients who do not respond to a dopamine antagonist, 
agents from different classes are combined. In patients with 
refractory nausea and vomiting, a broad spectrum agent 
which blocks multiple neurotransmitters should be added, 
such as olanzapine or methotrimeprazine.
Data on the effectiveness of the palliative care approach 
to choosing which antiemetic to prescribe is limited. 
  Effectiveness of the individual antiemetic agents is discussed 
in the next section. Using the mechanistic approach, con-
trolled studies of antiemetics in specific syndromes, such as 
cancer-associated dyspepsia syndrome and opioid-induced 
nausea have produced mixed results. Case series involving 
some 200 heterogeneous episodes found symptoms were 
controlled in 60%–90% cases, and residual symptoms were 
generally mild.11,39,46 On the other hand, three randomized 
trials and one observational study have evaluated the empiri-
cal approach.34,47–49 These studies are hard to synthesize and 
none was placebo-controlled. Nevertheless, low-dose 
  metoclopramide (10 mg three times a day) was effective in 
30%–40% of cases. Other agents, including a dopamine 
antagonist (in one of two studies) and a serotonin antagonist 
(one study) were superior to the other therapies. There have 
been no head-to-head comparisons of the mechanistic and 
empiric approaches. Cochrane reviews and other systematic 
Biochemical changes,
drugs
Raised
intracranial
pressure
Movement
Gastric stasis, constipation, bowel obstruction
Cerebral cortex
GABA
Pressure receptors
?
Chemoreceptor trigger zone
Dopamine, serotonin
Vestibular nucleus
Histamine, acetylcholine Vomiting center
Histamine, acetylcholine, serotonin
Gastrointestinal tract
Dopamine, serotonin
EMESIS
Anxiety
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reviews of treatment of nausea and vomiting in palliative 
care have been attempted, but the evidence that has been 
identified is sparse.50–52 Consequently, there is a dearth of 
specific recommendations or guidelines regarding drug selec-
tion, dosing, and side effects which account for changes in 
aging physiology, pharmacokinetics, and idiosyncratic reac-
tions other than what is provided in pharmacology texts.
Drugs for treating nausea  
and vomiting
Prokinetic agents
Prokinetic agents stimulate the motility of the upper gastro-
intestinal tract by four potential mechanisms: activation of 
5HT4 receptors, releasing acetylcholine from enteric neurons 
to stimulate the cholinergic system in the gut wall; blockade 
of 5HT3 receptors;53,54 activation of motilin receptors;55 or 
releasing the dopaminergic “brake” on gastric emptying.56 
Prokinetic agents should not be used when stimulation of 
muscular contractions might adversely affect the gut, for 
example, in complete bowel obstruction, gastrointestinal 
hemorrhage, perforation, or immediately following surgery. 
These prokinetic effects are blocked by antimuscarinic 
agents, including antihistamine antiemetics. Therefore, it 
makes no sense to prescribe a prokinetic and an antimusca-
rinic agent together.
Metoclopramide is the only prokinetic agent that is cur-
rently widely available. It works on the stomach and proximal 
small bowel, but has little effect on colonic motility. In addi-
tion to its prokinetic effects, metoclopramide also antago-
nizes D2+ receptors in the chemoreceptor trigger zone. The 
pharmacokinetics of metoclopramide are summarized in 
Table 5, along with most other antiemetics discussed in this 
section.
The prokinetic dose of metoclopramide is 10 mg three or 
four times a day, administered half an hour before meals and 
at bedtime. The central D2 antagonist effect of metoclopramide 
in the chemoreceptor trigger zone is only achieved with high 
doses (10 mg every 4–6 hours, orally or parenterally, maximum 
daily dose 100 mg). Dose reductions are recommended in 
moderate to severe renal impairment, with a 50% decrease 
recommended if the creatinine clearance is 10–40 mL/min, 
and a 75% reduction if the creatinine clearance 
is ,10 mL/min.57,58 In elderly patients, the initial dose should 
be at the lower end of the recommended adult range.
The most common side effects of metoclopramide are 
restlessness, drowsiness, and fatigue. Assessments for invol-
untary movements are recommended for elderly patients 
using metoclopramide at high doses and for long-term 
therapy. To highlight the risk of tardive dyskinesia from 
metoclopramide, the US Food and Drug Administration has 
added a “black box warning” to the information leaflet for 
prescribers; administration beyond 12 weeks is not recom-
mended. Pretreatment with diphenhydramine will prevent 
the acute extrapyramidal symptoms with high-dose 
metoclopramide,59 but may block the peripheral prokinetic 
effects. Other precautions relevant to the elderly when pre-
scribing metoclopramide include Parkinson’s disease, high 
blood pressure, kidney problems, liver problems, heart fail-
ure, and diabetes. Clinically important drug interactions are 
uncommon with metoclopramide because it is a minor sub-
strate of the cytochrome P450 (CYP) 1A2 and 2D6 isoen-
zymes and a weak inhibitor of CYP 2D6.
Three small placebo-controlled trials have evaluated the 
effectiveness of metoclopramide,34,60,61 but the results are 
conflicting. Metoclopramide was superior to placebo in 
cancer-associated dyspepsia syndrome,34 but not in 
Table 4 Receptor site affinities of commonly used antiemetics2,54,142
Drug Dopamine 
antagonist
Histamine 
antagonist
Acetylcholine  
(muscarinic)  
antagonist
Serotonin  
type 2 antagonist
Serotonin  
type 3 antagonist
Serotonin  
type 4 agonist
Chlorpromazine
Cisapride
Cyclizine
Domperidone
Haloperidol
Hyoscine
Levomepromazine
Metoclopramide
Ondansetron
Prochlorperazine
Promethazine
Notes: Black, high affinity for receptor; dark gray, moderate affinity; light gray, low affinity; white, no known affinity.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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  opioid-induced nausea.60 In a Spanish study, levosulpiride 
was superior to metoclopramide, effective in approximately 
85% versus 40% of cases.61
Other agents with prokinetic activity include mirtazap-
ine62 and erythromycin. Erythromycin acts by stimulating 
motilin receptors in the upper gastrointestinal tract.55 5HT3 
receptors may also be involved in this process.63 There are 
no data for its use in palliative care, but it has been shown to 
be effective in diabetic gastroparesis.64 The prokinetic dose 
is 250 mg three times a day by mouth or 250–500 mg per 
day intravenously. Side effects include impaired hepatic 
function and prolongation of the QTc interval on the electro-
cardiogram. Domperidone and cisapride are effective proki-
netic drugs that were formerly available,54,65 but have either 
been removed or are restricted because of their potential for 
cardiac toxicity associated with QTc prolongation.66–68 Dom-
peridone does not cross the blood–brain barrier, so only acts 
at peripheral dopamine receptors, releasing the “dopaminer-
gic brake”. As a result, extrapyramidal symptoms are much 
less likely with it. Cisapride is a pure 5HT4 receptor agonist 
that is devoid of any D2 antagonist activity, and is able to 
increase the motility of the entire length of the gastrointes-
tinal tract.69–71 It is prone to many drug interactions via CYP 
3A4 which increases its blood levels and aggravates its 
arrhythmogenic effect.
Dopamine receptor antagonists
Phenothiazines and other antipsychotic agents, such as halo-
peridol and olanzapine, block D2 receptors found in the 
chemoreceptor trigger zone.3 All but haloperidol has a broad 
spectrum of activity, also blocking histaminic, muscarinic, 
serotonergic, and/or alpha-adrenergic receptors. They may 
also produce vagal blockade in the gastrointestinal tract, giv-
ing them some prokinetic activity. They are also used in 
malignant bowel obstruction. Because of their broad activity, 
these agents cause many side effects, most notably sedation, 
hypotension, and anticholinergic side effects, dystonias, and 
extrapyramidal symptoms. They may prolong the QTc inter-
val, lower the white blood cell count, and lower seizure 
thresholds. Due to their side effect profile, they are not ideal 
agents to use in the elderly. These agents carry a “black box 
warning” about precipitation of psychosis in demented elderly 
patients. There is an increased risk of death compared with 
placebo, although most deaths are either cardiovascular or 
infectious in nature and not specifically related to the drug.
Prochlorperazine and chlorpromazine are two phenothi-
azines which are commonly used as antiemetics. The anti-
emetic dose of prochlorperazine is 5–10 mg three times a 
day or four times a day orally, 25 mg twice a day or three 
times a day rectally, or 5–10 mg every 3–4 hours (to a maxi-
mum of 40 mg daily) intramuscularly. The initial geriatric 
dose is 2.5–5 mg once or twice daily, increased once or twice 
Table 5 Pharmacokinetics of selected antiemetic drugs
Drug BA (%) Onset (h) Tmax (h) t½ (h) Duration (h)
Chlorpromazine143 10–69 – PO: 2–4 IM: 0.5–1 8–35 .24
Cisapride71 40–50 0.5–1 1–2 7–10 12–16
Cyclizine144 ,2 2. 7, 24 4–6
Dexamethasone100 61–86 8–24 1–2 4 36–54
Domperidone56,65,145,146 13–17 0.5 0.5 7.5–16 8–16
Haloperidol73 60–65 PO: . 1 SC: 0.15–0.25 PO: 1.7–6 IM: 0.3–0.5 14–36 –
Hyoscine butylbromide 8–10 PO: 1–2 SC: 0.25–0.5 – 5–6 –
Hyoscine hydrobromide147 Not applicable SL: 0.15–0.25 0.15–0.5 5–6 0.25–10
Levomepromazine76 50 0.5 PO: 1–3 IM 0.5–1.5 15–30 12–24
Metoclopramide148 32–100 Iv: 0.01–0.05 IM: 0.15–0.25 
PO: 0.5–1
,1 4–6 1–2
Octreotide149,150 Not applicable – ,0.5 1.5 8–12
Olanzapine151 60–80 – PO: 5–8 IM: 0.25–0.75 21–54
Prochlorperazine152,153 12.5 1.5–5 6.8–9
Promethazine154,155 25 PO: 2–3 10–14 4–12
Serotonin antagonists
Dolasetron156,157 76 – Iv: 0.6 PO: 1.4 6.6–8.8
Granisetron158 60 – PO: 2 10–12
Ondansetron159–161 60–70 – Iv: 0.1 PO: 0.5–2 2.5–5.4
Palonosetron162,163 N/A – 40
Tropisetron164,165 60–100 PO: 1–1.3 8–40
Abbreviations: BA, bioavailability; Tmax, time to reach maximum blood concentration (in hours); t½, elimination half-life; IM intramuscular; IV, intravenous; PO, oral; 
SC, subcutaneous; SL, sublingual; N/A, not available.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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a week by 2.5–5 mg/day, and the maximum daily dose should 
not exceed 75 mg. The antiemetic dose of chlorpromazine 
is 10–25 mg every 4–6 hours or 25–50 mg every 3–4 hours, 
orally.2 Dose reduction should be considered in the elderly 
and in patients with liver dysfunction. Chlorpromazine is 
more sedating than prochlorperazine,72 and this can be dose-
limiting, although it may be useful in a distressed dying 
patient. Prochlorperazine should also be avoided in patients 
with an absolute neutrophil count of ,1000 cells/µL because 
of the risk of neutropenia. Other side effects are common, 
including confusion, respiratory depression, extrapyramidal 
symptoms, and anticholinergic effects. Gradual titration may 
prevent some side effects or decrease their severity. General 
precautions in the elderly include glaucoma and prostate 
hypertrophy.
Haloperidol, a butyrophenone, is a more potent and pure 
D2 receptor blocker than the other agents.2 Antiemetic doses 
of haloperidol are 1.5–5 mg twice a day or three times a day 
by mouth, or 0.5–2 mg intravenously every 8 hours, and are 
lower than usual antipsychotic doses. The side effects of 
haloperidol are similar to those of the phenothiazines, except 
that haloperidol causes less sedation and hypotension. 
It causes more extrapyramidal symptoms, and patients with 
Parkinson’s disease may be more sensitive to its adverse 
effects, so it should be avoided in them. Haloperidol may 
also have enough anticholinergic activity to exacerbate 
narrow-angle glaucoma. Caution and dose reduction is rec-
ommended in patients with severe hepatic impairment. 
Haloperidol is a substrate of CYP 3A4, so coadministration 
with carbamazepine, phenytoin, phenobarbital, rifampicin, 
or quinidine may alter the clinical pharmacokinetics of halo-
peridol. It is a moderate inhibitor of CYP 2D6, but this has 
been reported to be of questionable clinical significance.73
Levomepromazine is utilized as second-line or third-line 
therapy for refractory nausea and vomiting in palliative care.74 
It also has analgesic properties.75 The dose is 6.25–25 mg 
twice a day, or 25–50 mg/day via continuous subcutaneous 
infusion. It presents the same potential problems in the elderly 
as the other dopamine antagonists, with anticholinergic 
effects, confusion, hallucinations, and dystonic reactions all 
possible. Compared with chlorpromazine, it is more sedative 
and more likely to cause postural hypotension.74 It should be 
administered cautiously in renal or hepatic impairment.76 
It may prolong the QT interval.
Olanzapine is an atypical antipsychotic with high affinity 
for multiple dopamine (D1, D2, D4), serotonin (5HT2A, 5HT2C, 
5HT3), α1-adrenergic, H1, and cholinergic (M1–5) receptors.77,78 
It has been used as an antiemetic in palliative care.79 The usual 
antiemetic dose is 5–10 mg/day by mouth.59 A lower starting 
dose (2.5–5 mg/day) is recommended for elderly or debili-
tated patients, which may be increased as tolerated with close 
monitoring of orthostatic blood pressure. Olanzapine causes 
fewer extrapyramidal symptoms than other antipsychotics,80,81 
and it does not usually cause QTc prolongation at conven-
tional doses. Its main side effects are somnolence and weight 
gain. Dry mouth, constipation, increased appetite, agitation, 
hyperglycemia, and edema have also been reported.81 
  Olanzapine is only a weak inhibitor of the CYP isoenzymes, 
so drug interactions are not usually an issue. Precautions to 
consider in the elderly palliative care patient when prescrib-
ing olanzapine include severe cardiac disease, hemodynamic 
instability, prior myocardial infarction, ischemic heart dis-
ease, or hypercholesterolemia, Parkinson’s disease, and renal 
or hepatic impairment.
Although haloperidol and the other dopamine antagonists 
are frequently used for nausea or vomiting in palliative care, 
the evidence supporting their use is scant:
•	 Prochlorperazine – there are no data for this agent as an 
antiemetic in advanced cancer. It is significantly less 
effective than high-dose metoclopramide for chemother-
apy-induced emesis.82
•	 Chlorpromazine – in large randomized controlled trials 
of empiric prescribing of antiemetics,49 chlorpromazine-
containing combinations were effective only 20%–30% 
of the time.
•	 Haloperidol – there have not been any randomized con-
trolled trials of haloperidol for the other chronic nausea 
syndromes in palliative care other than malignant bowel 
obstruction.50,83,84 There have been randomized controlled 
trials of haloperidol in postoperative nausea and vomiting, 
gastrointestinal disorders, and prophylaxis against che-
motherapy-induced emesis. The number-needed-to-treat 
for haloperidol 2 mg to prevent postoperative nausea and 
vomiting was four.85
•	 Olanzapine – there are no randomized controlled trials 
of olanzapine for chronic nausea in palliative care. Two 
small case series with subjective outcome assessment 
indicated that olanzapine appears to be effective in cases 
that were refractory to other agents.86
•	 Levomepromazine – there have not been any random-
ized controlled trials of levomepromazine in palliative 
care. In one case series, levomepromazine was used 
effectively as the first-line agent in 12% of patients; two 
other patients were switched to it when not responding 
to other agents.39 In other case series, it was effective 
in 60%–80% cases.37,87Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Antihistaminic agents
The first generation of piperazine class H1 receptor antagonists 
block H1 receptors in the vomiting center of the medulla,88 
the vestibular nucleus, and the chemoreceptor trigger zone.89,90 
The antimuscarinic activity does reduce mucosal secretory 
activity, which is helpful in bowel obstruction. There are 
many drugs in this class, including promethazine, cyclizine, 
meclizine, hydroxyzine, and diphenhydramine, all of which 
have potential as antiemetics.
Promethazine is widely prescribed for motion sickness 
and vestibular disorders, but may also help in emesis related 
to raised intracranial pressure. It has little anticholinergic 
activity. The antiemetic dose is 25 mg orally or intravenously 
every 4–6 hours (maximum 100 mg/day).91 The lowest doses 
should be used, and in divided doses to avoid side effects .
The main side effect is sedation, although tolerance usually 
develops quickly. Promethazine theoclate may cause less 
drowsiness  than  promethazine  maleate.  As  with 
  phenothiazines, the piperazine H1 receptor antagonists may 
cause dizziness, extrapyramidal symptoms, headache, con-
stipation, urinary retention, and lowering of the seizure 
threshold. It is recommended to limit the use of promethazine 
in the elderly, and discontinue it when not effective, due to 
its anticholinergic side effects. They may cause confusion 
or aggravate symptoms of confusion in those with dementia. 
H1 blockers should be used with caution in patients with 
narrow-angle glaucoma, prostatic hyperplasia, cardiovascular 
disease, severe hypertension, respiratory compromise, 
impaired hepatic function, and epilepsy.
Other H1 antagonists, such as diphenhydramine, dimen-
hydrinate, hydroxyzine, meclizine, and cyclizine, are men-
tioned as antiemetics in palliative care texts. They vary in their 
muscarinic activity, and those with more antimuscarinic activ-
ity, such as cyclizine, may be useful for bowel obstruction.92 
All are problematic in geriatric populations, but diphenhy-
dramine and hydroxyzine have a high risk for a severe adverse 
outcome on the Beers criteria, which rate a drug’s tendency 
to cause side effects in the elderly due to the physiologic 
changes of aging.93 Therefore, they are the least desirable in 
this population. Being a moderate CYP 2D6 inhibitor, diphen-
hydramine may diminish the metabolic activation and thera-
peutic effects of codeine, tramadol, and tamoxifen, which are 
potentially relevant in a palliative care population. Although 
prochlorperazine is mainly a dopamine antagonist, it also has 
some antihistamine activity and may be effective for mild 
cases of nausea due to a vestibular mechanism.
There are few published data for using H1 blockers as 
antiemetics in palliative care. There have been no randomized 
controlled trials,94 but in one uncontrolled trial of the   mechanistic 
approach to treating nausea, 5%–10% cases were initially 
treated with cyclizine, apparently successfully.39
Selective 5HT3 receptor antagonists
The selective 5HT3 receptor antagonists exert their antiemetic 
effect via blockade of peripheral and central 5-HT3 receptors. 
These receptors are found on the vagus nerve, which feeds 
into the emetic center, the enterochromaffin cells of the 
peripheral enteric nervous system, and in the nucleus tractus 
solitarius and chemoreceptor trigger zone.95 The 5HT3 recep-
tor antagonists block the amplifying effect of serotonin on 
the vagus nerve. They are primarily used for chemotherapy-
induced emesis and have a limited role in palliative care 
where they are generally reserved as third-line agents for 
refractory cases. They have also been shown to be effective 
in bowel obstruction and renal failure, both of which are also 
associated with excess serotonin release.
Ondansetron is the oldest selective 5HT3 receptor 
  antagonist. Newer ones include granisetron, tropisetron, 
dolasetron, and palonosetron. The recommended dose of 
ondansetron for chronic nausea is 4–8 mg given once or twice 
a day. Appropriate doses of the other agents are 1 mg twice 
a day for granisetron, 200 mg once a day for dolasetron, and 
0.25 mg intravenously once a day for palonosetron. Side 
effects of these agents are usually mild and transient. 
  Constipation, which may occur in 5%–10% of patients, is 
the biggest potential problem for palliative care patients. 
All selective 5HT3 receptor antagonists are metabolized by 
CYP isoenzymes, although the extent of metabolism and the 
specific isoenzymes involved differs for each drug. This has 
potentially significant clinical implications for patients 
receiving multiple medications. The selective 5HT3 receptor 
antagonists may decrease the efficacy of tramadol. They 
should be used cautiously with drugs that prolong the QTc 
interval. In severe hepatic impairment, the maximum dose 
is 8 mg/day.96
The selective 5HT3 receptor antagonists have been associ-
ated with a number of dose-dependent increases in electro-
cardiographic intervals including QT/QTc. Reduction in heart 
rate may also occur with these agents but they are considered 
to be reasonably safe in the elderly. Even though the elderly 
have a slightly decreased hepatic clearance rate of ondanse-
tron, this does not require dose adjustment.
It is noteworthy that several other antiemetic agents have 
nonselective activity at serotonin receptors. Metoclopramide 
is a weak 5HT3 receptor antagonist as well as a 5HT4 agonist 
(contributing to its prokinetic effect). Cisapride is a more Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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potent 5HT4 agonist than metoclopramide, without 5HT3 
antagonist activity. Olanzapine has activity at 5HT2A, 5HT2c, 
and 5HT3. The antidepressant mirtazapine also has some 
activity as a 5HT3 receptor antagonist.62 Levomepromazine 
is a potent 5HT2 antagonist but has no activity at the 5HT3 
or 5HT4 receptor; this 5HT2 antagonism may be important 
for controlling nausea.
Although there is high-level evidence for 5HT3 receptor 
antagonist agents in chemotherapy-induced emesis,97 the 
evidence of benefit for refractory nausea in palliative and 
supportive care is less strong.49,60,98 There have been two 
randomized controlled trials of 5HT3 receptor antagonists in 
advanced cancer.49,60 In one study, tropisetron was much more 
effective than conventional antiemetics (metoclopramide and 
chlorpromazine) for any cause of nausea in cancer patients.49 
In the other study, there were no significant differences 
between ondansetron, metoclopramide, and placebo for 
opioid-induced nausea in patients with advanced cancer.60 
Control of emesis and partial control of nausea was achieved 
in approximately 50% of patients on the active agents, com-
pared with 33% receiving placebo, but the difference was 
not significant. An uncontrolled case series of ondansetron, 
with rigorous outcome assessment, showed that it is effective 
as a second-line agent in 80% of patients.
Other agents
Corticosteroids
Corticosteroids have mainly been studied as antiemetics in 
chemotherapy-induced emesis, in the management of malig-
nant bowel obstruction,97,99 and raised intracranial pressure. 
They are also used as second-line therapy in chronic nausea 
of advanced cancer.48 Steroids are said to act “centrally”, but 
the precise antiemetic mechanism of action of steroids is 
unknown. Possible mechanisms include depletion of gamma 
aminobutyric acid stores in the medulla, reduction of blood–
brain barrier permeability to emetic toxins, and inhibition of 
enkephalin release in the brainstem.88 The usual antiemetic 
dose of dexamethasone is 4–8 mg/day for chronic nausea 
and up to 16 mg/day for malignant bowel obstruction or 
raised intracranial pressure.8 The lowest possible dose should 
be used for the briefest period, with withdrawal or reduction 
considered when maximal effect has been obtained, an 
adequate trial (approximately 7–10 days) has failed to achieve 
the desired effect, or if side effects occur. If dexamethasone 
is to be continued long term, prophylactic cotrimoxazole for 
prevention of Pneumocystis pneumonia is recommended. 
Because of its many side effects and toxicities,100 dexametha-
sone needs to be used with caution in diabetics, patients with 
a psychiatric history, and perioperatively. It may be 
  contraindicated in patients on palliative chemotherapy 
because of the risk of sepsis or masking a fever. There is 
limited and conflicting data on the benefit of steroids in chronic 
nausea due to nonspecific causes in terminal cancer.88 Reported 
efficacy rates vary from less than 20% to greater than 75%.48,49 
  Randomized controlled trials are lacking, but an uncontrolled 
trial of metoclopramide found 75% cases were controlled when 
steroids were added as second-line agents.
Benzodiazepines
Short-acting benzodiazepines such as lorazepam are fre-
quently administered to nauseated patients,72 but they are 
only minimally effective as antiemetics. Rather, their seda-
tive, anxiolytic, and amnesic properties may enhance the 
effectiveness of other antiemetic regimens and they may 
prevent the development of anticipatory emesis. They are 
most useful when nausea and vomiting is associated with 
anxiety. Benzodiazepines are generally to be avoided in 
elderly patients because of their high severity rating on the 
Beers criteria. If a benzodiazepine must be used, lorazepam 
is preferred because it is relatively short-acting and has inac-
tive metabolites.
Hyoscine
Pure anticholinergic agents such as hyoscine (also known as 
scopolamine) are used as antiemetics. Because they relax 
smooth muscle and reduce gastrointestinal secretions via 
blockade of muscarinic receptors, they are also useful in the 
medical management of terminal bowel obstruction. 
  Formulations (with antiemetic dose ranges) include hyoscine 
butylbromide (80–120 mg daily, via continuous subcutaneous 
infusion) and hyoscine hydrobromide (given orally, 
0.1–0.4 µg every four hours, subcutaneously or intravenously, 
0.6–2.4 mg daily via continuous infusion, or 1–3 mg trans-
dermally, changed every third day). The anticholinergic 
effects of hyoscine are a potential problem in the elderly.
Octreotide
This somatostatin analog is used for the palliation of malig-
nant bowel obstruction, especially when there is high output 
vomiting not responding to other measures (steroids, halo-
peridol, hyoscine, and a proton pump inhibitor). In this situ-
ation, octreotide reduces secretion of fluids by the intestine 
and pancreas,101 reduces gastrointestinal motility, and causes 
vasoconstriction. It has also been shown to produce analgesic 
effects, most probably acting as a partial agonist at the 
µ-opioid receptor.102 The dose used for bowel obstruction is Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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100 µg subcutaneously three times daily or 100–600 µg per 
day via intravenous or continuous subcutaneous infusion. 
The most common (in more than 10% of patients) side effects 
of octreotide are local skin reactions, including pain, stinging, 
burning, and gastrointestinal effects, including cramps, 
nausea/vomiting, diarrhea or constipation, and gallstones. 
Headache, hypothyroidism, and cardiac toxicity, including 
bradycardia and QTc prolongation, may be common. Because 
of its effects on insulin and other hormones, it should be used 
with caution in patients with diabetes mellitus and other 
endocrinopathies, renal failure, and hepatic impairment.
Cannabinoids
Many jurisdictions are currently considering the legalization 
of “medical marijuana”, and there are data for the efficacy 
of cannabinoids in chemotherapy-induced emesis and the 
anorexia-cachexia syndrome.103,104 There is little clinical 
evidence for the efficacy of cannabinoids in nausea and 
vomiting in palliative care, other than a few case reports. The 
antiemetic effect is thought to be subtended via CB1 receptors 
which are ubiquitous in brain tissue,103,105 but whether they 
are found within specific structures of the emetic pathway is 
unclear. Short duration of action and side effects are a major 
problem of current commercial formulations, such as dron-
abinol, especially in the elderly, who may be more sensitive 
to the central nervous system effects and postural hypotensive 
effects.106 The dose should be titrated slowly, with close 
monitoring for adverse effects. Drug interactions are uncom-
mon, but the central nervous system depressant effects may 
be potentiated when used with other psychoactive drugs, 
sedatives, and/or ethanol.
Other modes of nausea control
Nondrug measures are also important in the management of 
nausea and vomiting in palliative care. Avoidance of envi-
ronmental stimuli, such as sights, sounds, or smells that may 
initiate nausea are recommended.107 Fatty, spicy, and highly 
salted food should be avoided. Fish oil supplements failed 
to improve nausea, appetite, or tiredness in patients with 
advanced cancer.108
Behavioral approaches, such as relaxation and distraction, 
may decrease psychological arousal and distress by refocus-
ing the patient’s attention on something else, and increase 
the patient’s feelings of control over the symptoms.109 There 
have been few studies of these therapies in the chronic nausea 
of advanced cancer unrelated to anticancer treatment. 
  Relaxation training which utilizes progressive muscle relax-
ation and guided imagery has been successful in reducing 
chemotherapy-induced emesis in some studies110,111 but not 
others.112 Massage has been reported to be effective for nausea 
and pain in bone marrow transplant patients.113 Foot massage 
was shown to reduce nausea significantly in hospitalized 
cancer patients.114
A systematic review of complementary and alternative 
medicine for symptom management at the end of life was 
unable to identify any large-scale trials in terminally ill 
patients for nausea and vomiting. Only studies for chemo-
therapy-induced emesis could be found.115 Acupuncture and 
ginger have been shown to be effective for chemotherapy-
induced emesis and anticipatory nausea,51,116 but have not 
been evaluated in the nausea of far advanced disease.
Nonsurgical procedures in palliation 
of cancer-related nausea  
and vomiting
While some patients prefer to die without tubes, as presented 
in the case history in the Introduction,4 palliation of nausea and 
vomiting may be achieved more quickly and effectively in 
patients with advanced disease who are not amenable to surgery 
when draining percutaneous gastrostomy tubes,   gastrointestinal 
stents, and other endoscopic techniques are utilized. Progress 
in interventional gastroenterology makes these approaches less 
risky and burdensome than they used to be.
Three percent of all advanced cancers lead to malignant 
bowel obstruction, particularly bowel cancer and ovarian 
cancer.1,117 In fact, some 25%–50% patients with ovarian 
cancer experience at least one episode of malignant bowel 
obstruction. Surgery may not be an option when there is 
diffuse intraperitoneal metastasis with multiple areas of 
obstruction or advanced stage of disease with very short 
life expectancy. In this situation, other modalities such as 
percutaneous endoscopic gastrostomy (PEG) placement   
can be considered.118 Nasogastric tubes are less invasive 
than a PEG tube but should not be used over an extended 
period of time. Nasogastric tubes risk frequent displace-
ment, poor tolerance, and restrictions in ambulation and 
daily routine activities. Complications of nasogastric tubes 
include aspiration, hemorrhage, gastric erosion, alar necro-
sis, and sinusitis or otitis.
The most common approach for placement of gastros-
tomy tubes is endoscopic. The success rate of PEG placement 
is very high, in the range of 89%–100%,119–122 and symptom-
atic improvement can usually be expected. Once a PEG tube 
is placed, most patients are able to go home or into an inpa-
tient hospice facility to die. Most can take sips, liquids, or a 
soft diet, with or without the tube being clamped.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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PEG tube maintenance is relatively simple but does 
require education of the patient and their informal caregivers. 
The complication rate of PEG tubes has been summarized 
in a review of seven studies involving almost 300 patients. 
In the largest series, major and minor complications of PEG 
placement affected 18% of the patients, with half of 
them (9%) complaining of ascites and leakage.119 Other 
reported complications in this series included peristomal 
infection, tube obstruction, tube migration, and wound 
  bleeding. In a small study utilizing the Symptom Distress 
Scale, 64% of patients reported improvement in nausea, 
vomiting, intestinal motility, insomnia, weakness, mood, and 
concentration 7 days after PEG placement.123
Partial or complete obstruction by tumors of the esopha-
gus, stomach, duodenum, or colon are frequently complicated 
by nausea and vomiting. Blockage of the lumen by tumor 
may occur directly or by extrinsic compression. In locally 
advanced esophageal cancer, palliative management of an 
obstructing lesion includes alcohol injection,124,125 laser 
therapy,126,127 argon plasma coagulation,128 photodynamic 
therapy, and esophageal stent placement, which can be 
plastic,129–131 or metallic.132–136 Stent migration rates are 
reported to range from 6% to 25%. Gastric outlet obstruction 
is associated with vomiting undigested food hours after eat-
ing. The most common nonsurgical treatment is enteral stent 
placement.137 Because gastric outlet obstruction is frequently 
associated with biliary tract obstruction, simultaneous place-
ment of a biliary stent and an enteral stent is recommended.
In malignant large bowel obstruction, colonic decompres-
sion tubes, laser therapy, argon plasma coagulation, and self-
expanding metal stents have all been employed. Colonic 
decompression tube placement is often used to provide air (and 
not necessarily stool) passage in patients who need clinical 
stabilization before surgery.138 The stents used for large bowel 
obstruction are self-expanding metallic stents. Studies that 
compared self-expanding metallic stents with surgery have 
shown the benefits of self-expanding metallic stent placement, 
including a decreased length of hospitalization and cost.139–141
Conclusion
Recent large surveys and reviews indicate that nausea and 
vomiting are less frequent and distressing in patients at the 
end of life than other symptoms, such as pain, fatigue, or 
breathlessness. Data for the efficacy of antiemetic agents in 
advanced cancer are limited, and where they exist they are 
often conflicting. Novel agents are also needed, but the 
known neuropharmacology of the antiemetic pathway may 
not be the most appropriate paradigm for chronic nausea 
from other causes. Novel agents, such as cannabinoids and 
anticytokine antibodies, may prove useful. In the meantime, 
more studies are needed of both the existing drugs and the 
different approaches to selecting them (empirical versus 
mechanistic). To achieve valid and reliable results, these 
studies will need to overcome many methodological chal-
lenges that are encountered when studying symptoms in 
patients with advanced diseases.
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